The role of intra-abdominal chemotherapy in inoperable gastric cancer to change to operable tumor

The role of intra-abdominal chemotherapy in inoperable gastric cancer to change to operable tumor in case-control study about one year survival and improve quality of life

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201107257112N1

Enrollment

Registered

2011-10-03

Start date

2011-09-16

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer. Malignant neoplasm of stomach

Interventions

Intervention 1: Intervention group: a peritoneal dialysis catheter is inserted to around the adherence area and its distal is brought out the skin. 10 days after the operation, mitomycin -cisplatin-5

Treatment - Other

Intervention group: a peritoneal dialysis catheter is inserted to around the adherence area and its distal is brought out the skin. 10 days after the operation, mitomycin -cisplatin-5 Fluorouacil will

Control group: The abdomen will be closed without any intervention or receiving peritoneal chemotherapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: presence of criteria for diagnosis as inoperable patient including: 1-local invasion to retroperitoneal organs including: Great veins like aorta-celiac body and solid organs like pancraces. 2 - peritoneal or omentum seeding or metastatic tumor like krukenberg tumor Exclusion criteria: presence of ascites or metastasis, old age (more than 65 years old), cachectic patients with albumin less than 3 and edema

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
One year survival. Timepoint: 6 months after the end of trial. Method of measurement: Follow up the patients.;Quality of life. Timepoint: 6 months after the end of trial. Method of measurement: Follow up the patients.	—

Secondary

Measure	Time frame
Tumor perforation. Timepoint: Beginning of trial to 6 months after trial. Method of measurement: Follow the patients and study quality of patient`s life.;Great vesseles perforation. Timepoint: Beginning of trial to 6 months after trial. Method of measurement: Follow the patients and study quality of patient’s life.;Vomitting. Timepoint: Beginning of trial to 6 months after trial. Method of measurement: Follow the patients and study quality of patient’s life.;Nausea. Timepoint: Beginning of trial to 6 months after trial. Method of measurement: Follow the patients and study quality of patient`s life.;Intra abdominal infection. Timepoint: Beginning of trial to 6 months after trial. Method of measurement: Follow the patients and study quality of patient’s life.	—

Measure

Time frame

Tumor perforation. Timepoint: Beginning of trial to 6 months after trial. Method of measurement: Follow the patients and study quality of patient`s life.;Great vesseles perforation. Timepoint: Beginning of trial to 6 months after trial. Method of measurement: Follow the patients and study quality of patient’s life.;Vomitting. Timepoint: Beginning of trial to 6 months after trial. Method of measurement: Follow the patients and study quality of patient’s life.;Nausea. Timepoint: Beginning of trial to 6 months after trial. Method of measurement: Follow the patients and study quality of patient`s life.;Intra abdominal infection. Timepoint: Beginning of trial to 6 months after trial. Method of measurement: Follow the patients and study quality of patient’s life.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ramin Azhough

Tabriz University of Medical Sciences

azhoughr@tbzmed.ac.ir+98 41 1334 1317

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026